AZ Delta | Clinical Trial Center - Pneumology

Research site

(Unclaimed)

Location

Deltalaan 1, Roeselare, West Flanders, Belgium

Site insights

Top conditions

Top treatments

Pembrolizumab

LY3298176

Tirzepatide

Selpercatinib

Alimta

Dostarlimab

Apixaban

Azacitidine

Elranatamab

Retatrutide

Parent organization

This site is a part of AZ Delta vzw

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 24 total trials

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocy...

Enrolling

Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia

Drug: Pirtobrutinib

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Active, not recruiting

Atrial Fibrillation

Drug: Apixaban Placebo

Drug: Milvexian

A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients (PULMO-01)

The goal of this clinical trial is to learn how roginolisib works in combination with dostarlimab with or without docetaxel in adult patients with ad...

Enrolling

Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Advanced Non Squamous NSCLC

Drug: Docetaxel

Drug: Dostarlimab

A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) (LIBRETTO-432)

The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in particip...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Placebo

Drug: Selpercatinib

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% (RELATIVITY1093)

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy...

Enrolling

Non-small Cell Lung Cancer

Drug: Relatlimab

Drug: Nivolumab

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (TroFuse-015)

This study will compare how safe and effective sacituzumab tirumotecan is versus the treatment of physician's choice (TPC) in participants with advan...

Enrolling

Gastroesophageal Cancer

Drug: Rescue medication

Drug: Supportive care measures

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) (SOHO-02)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called hu...

Enrolling

HER2 Mutation

Advanced Non-small Cell Lung Cancer

Drug: Cisplatin

Drug: Pembrolizumab

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative ne...

Active, not recruiting

Anemia

Myelofibrosis

Other: Placebo

Drug: ACE-536

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants wit...

Active, not recruiting

Colorectal Cancer

Biological: MK-4830

Biological: Pembrolizumab/Quavonlimab

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC), a group of lung cancers that have spre...

Active, not recruiting

EGFR Mutation

HER2 Mutation

Drug: BAY2927088_formulation A

Drug: BAY2927088_formulation B_2

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the t...

Enrolling

Multiple Myeloma

Drug: Pomalidomide

Drug: Elotuzumab

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tu...

Active, not recruiting

Neoplasm Malignant

Drug: Pembrolizumab

Drug: Lenvatinib

Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC

PDC-LUNG-101 trial is an open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary...

Active, not recruiting

Non Small Cell Lung Cancer

Biological: PDC*lung01

Drug: Alimta Injectable Product

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer (SUNRAY-02)

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo comb...

Enrolling

Carcinoma, Non-Small-Cell Lung

Drug: Olomorasib

Drug: Placebo

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia (SHASTA-3)

This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (...

Active, not recruiting

Severe Hypertriglyceridemia

Drug: Plozasiran Injection

Drug: Placebo

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Chronic Kidney Disease (CKD)

Drug: Retatrutide

Drug: Placebo